Adjuvant Dose-Dense Sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study

Author： Papadimitriou Christos   Papakostas Pavlos   Timotheadou Eleni   Aravantinos Gerasimos   Bamias Aristotelis   Fountzilas George  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.26, Iss.5, 2008-06, pp. : 491-498

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite

Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: A Hellenic Cooperative Oncology Group (HeCOG) phase II study

By Makatsoris Thomas   Papakostas Pavlos   Kalofonos Haralabos   Xanthakis Ioannis   Tsavdaridis Dimitrios   Aravantinos Gerasimos   Gogas Helen   Klouvas George   Kosmidis Paris   Pectasides Dimitrios   Fountzilas George  

Medical Oncology, Vol. 24, Iss. 3, 2007-09 ,pp. : 301-307

Humana Press, Inc

Access to resources Recommend Favorite

Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: A Hellenic Cooperative Oncology Group (HeCOG) study

By                                  

Oncology Reports, Vol. 27, Iss. 1, 2012-01 ,pp. : 216-224

Spandidos Publications

Access to resources Recommend Favorite

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

By Bamias A.   Dafni U.   Karadimou A.   Timotheadou E.   Aravantinos G.   Psyrri A.   Xanthakis I.   Tsiatas M.   Koutoulidis V.   Constantinidis C.   Hatzimouratidis C.   Samantas E.   Visvikis A.   Chrisophos M.   Stravodimos K.   Deliveliotis C.   Eleftheraki A.   Pectasides D.   Fountzilas G.   Dimopoulos M. A.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1011-1017

Oxford University Press

Access to resources Recommend Favorite

Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study

By Christodoulou Christos   Bafaloukos Dimitrios   Linardou Helen   Aravantinos Gerassimos   Bamias Aristotelis   Carina Maria   Klouvas George   Skarlos Dimosthenis  

Journal of Neuro-Oncology, Vol. 71, Iss. 1, 2005-01 ,pp. : 61-65

Springer Publishing Company

Access to resources Recommend Favorite